BioCardia jumps after FDA minutes clarify PMA path for CardiAMP HF II trial

BioCardia, Inc. (BCDA) is up 52.3% today. Here is some analysis on what might have caused this price movement.

Analysis: Shares appear to be reacting to a regulatory update indicating BioCardia’s ongoing CardiAMP Heart Failure II trial may support a Premarket Approval (PMA) submission, improving perceived odds and visibility on a commercial pathway. Given the company’s tight liquidity and listing-compliance overhang, any de-risking regulatory signal can trigger an outsized move in a small-cap, high-volatility name.

Details:

BioCardia released FDA meeting minutes from a Q-Submission interaction stating the ongoing CardiAMP HF II trial may support a PMA application for the CardiAMP Cell Therapy System in ischemic heart failure with reduced ejection fraction.

The company framed the completed CardiAMP HF data as supportive evidence alongside HF II, while noting PMA is a rigorous pathway for high-risk medical devices.

In its Form 10-Q for the quarter ended March 31, 2026, BioCardia disclosed cash and cash equivalents of $951,000 and stated this was not sufficient to fund obligations beyond June 2026 absent additional financing, raising going-concern uncertainty.

The same 10-Q discussed a Nasdaq continued-listing compliance matter tied to minimum stockholders’ equity requirements, which can heighten sensitivity to positive catalysts.

Sources:

GlobeNewswire, U.S. SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BCDA Insider Trading Activity

$BCDA insiders have traded $BCDA stock on the open market 14 times in the past 6 months. Of those trades, 14 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BCDA stock by insiders over the last 6 months:

PETER ALTMAN (President and CEO) has made 14 purchases buying 26,400 shares for an estimated $28,194 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive BCDA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BCDA Hedge Fund Activity

We have seen 10 institutional investors add shares of $BCDA stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DRW SECURITIES, LLC removed 57,607 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $69,704
VANGUARD GROUP INC added 39,063 shares (+40.5%) to their portfolio in Q4 2025, for an estimated $48,828
PINGORA PARTNERS LLC added 32,703 shares (+1077.2%) to their portfolio in Q1 2026, for an estimated $39,570
CITADEL ADVISORS LLC removed 30,863 shares (-32.7%) from their portfolio in Q1 2026, for an estimated $37,344
GEODE CAPITAL MANAGEMENT, LLC added 28,284 shares (+42.9%) to their portfolio in Q1 2026, for an estimated $34,223
VIRTU FINANCIAL LLC added 20,355 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,629
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC removed 20,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $24,200

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.